JESÚS MARÍA
BAÑALES ASURMENDI
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (8)
2022
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
-
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
Gut, Vol. 70, Núm. 7, pp. 1345-1361
2019
-
Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib
British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800
2018
-
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344